Solid Tumors Harboring Braf V600 Mutation

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-03-13
Clinical Trial Update: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors [Phase 1, Phase 2]
Phase Ib/II trial evaluating LGX818 in combination with MEK162 for BRAF V600-mutant solid tumors has completed with posted results.